Navigation Links
Poniard Pharmaceuticals To Present at Three Upcoming Investor Conferences in September
Date:9/2/2009

SOUTH SAN FRANCISCO, Calif., Sept. 2 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced that Jerry McMahon, Ph.D., chairman and chief executive officer, is scheduled to provide a corporate overview, including a discussion about the clinical development program for the Company's lead product candidate, picoplatin, at three upcoming investor conferences:

  • Baird Healthcare Conference
    • Wednesday, September 9, 2009 at 1:15 p.m. Eastern Time
    • Four Seasons Hotel in New York City

  • Rodman & Renshaw 11th Annual Healthcare Conference
    • Thursday, September 10, 2009 at 10:25 a.m. Eastern Time
    • The Palace Hotel in New York City

  • NewsMakers in the Biotech Industry Conference
    • Wednesday, September 16, 2009 at 11:30 a.m. Eastern Time
    • Millennium Broadway Hotel in New York City

Live audio web casts of Poniard's presentations will be available for 10 business days on the "Events" page of the "News & Events" section of the Company's Web site at http://www.poniard.com.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum chemotherapy. To date, clinical studies suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and castration-resistant (hormone refractory) prostate cancers. The Company also is conducting a clinical trial of oral picoplatin in solid tumors. For additional information please visit http://www.poniard.com.

(C) 2009 Poniard Pharmaceuticals, Inc. All Rights Reserved.

Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.


'/>"/>
SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update
2. Poniard Pharmaceuticals to Host Second Quarter 2009 Financial Results Conference Call on August 4
3. Poniard Pharmaceuticals Appoints Gary A. Lyons to Board of Directors
4. Poniard Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
5. Poniard Pharmaceuticals Files Shelf Registration
6. Poniard Pharmaceuticals to Present at the Leerink Swann Oncology Roundtable Conference
7. Poniard Pharmaceuticals to Present at the 2009 BIO International Convention
8. Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer
9. Poniard Pharmaceuticals to Present Final Data from Picoplatin Phase 1 Clinical Trials at American Association for Cancer Researchs 100th Annual Meeting
10. Poniard Pharmaceuticals Reschedules Fourth Quarter and Fiscal 2008 Results Conference Call for Monday, March 16
11. Poniard Pharmaceuticals to Host Fourth Quarter and Year-End 2008 Financial Results Conference Call on March 12
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... , ... June 22, 2017 , ... Charm Sciences, Inc. ... The AMPH test was determined to be appropriate as a screening test at dairies ... on the Charm EZ system, and the Charm EZ Lite system. These systems are ...
(Date:6/20/2017)...  Kibow Biotech Inc., a pioneer in developing "Enteric ... a new patent covering a unique method for preventing ... and Trademark Office on May 23 rd 2017. ... Bio award in 2014 in San Diego, ... to chronic disease. Renadyl™, the first and only dietary ...
(Date:6/19/2017)... ... June 19, 2017 , ... ... service activities supporting EDETEK’s products including training, implementation, support, and client process and ... new role. He has previously held leadership roles for service providers and top-tier ...
(Date:6/16/2017)... ... June 16, 2017 , ... ... has just announced two more sessions of its “From the Helm” Webinar Series. ... the world of online templates for design control exercises. Led by David Cronin, ...
Breaking Biology Technology:
(Date:4/11/2017)... 11, 2017 Research and Markets has announced ... report to their offering. ... global eye tracking market to grow at a CAGR of 30.37% ... Tracking Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
(Date:4/5/2017)...  The Allen Institute for Cell Science today announces ... portal and dynamic digital window into the human cell. ... application of deep learning to create predictive models of ... a growing suite of powerful tools. The Allen Cell ... publicly available resources created and shared by the Allen ...
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
Breaking Biology News(10 mins):